DALE BROWN

Dale  Brown is a growth-oriented healthcare executive and seasoned board director with a proven record of advancing start-up and multi-billion-dollar organizations in the U.S. and internationally.  Dale will bring significant value to our clients in our AI and pharmaceutical consulting.

Dale has made significant contributions in the pharmaceutical marketplace for personalizing and optimizing patient care through increased access to pharmacogenetics (PGx), digital therapeutics (DTx) and other diagnostics.

Personally, he dedicates his time and commitment to advancing cancer treatment through board service advising companies using AI to assist oncologists in the selection of a combination of cancer drugs. 

Dale received his MBA in Finance and Marketing from the University of Chicago Booth School of Business and his Bachelor’s degree in Medical Sociology from the University of Illinois. More recently, he completed the "Artificial Intelligence in Healthcare" certificate programs at both Stanford and MIT. 

In addition to his role as CEO of MedPGx, Dale serves as a Board Director to CureMatch and a Strategic Advisor to CureMetrix, both are artificial intelligence companies advancing cancer detection and treatment. 

Previously, Dale accepted the role of CEO of MedImpact Healthcare System and added the president’s responsibilities, which included leading the company’s subsidiaries: MedImpact International, MedImpact Direct, ScriptSave, and SUNRx (340B).  

Dale also served on the boards of MedImpact Holdings, MedImpact International, and MedImpact Arabia.  Additionally, Dale served on the Board of Ardon Health a leading Specialty Pharmacy, and served on the Board of PCMA with other PBM industry CEOs.  Dale has held various leadership roles at Humana, CVS Caremark, Express Scripts, and Cardinal Health.